Development of macrolide resistance and reinfection in refractory Mycobacterium avium complex lung disease

Byung Woo Jhun, Su Young Kim, Seong Mi Moon, Kyeongman Jeon, O. Jung Kwon, Hee Jae Huh, Chang Seok Ki, Nam Yong Lee, Sung Jae Shin, Charles L. Daley, Won Jung Koh

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Rationale: Patients with refractory Mycobacterium avium complex lung disease (MAC-LD) undergo long-term macrolide therapy, but macrolide resistance develops infrequently. Objectives: The aim of this study was to determine whether reinfection was a factor in the low incidence of macrolide resistance in patients with refractory MAC-LD. Methods: Among 481 patients with treatment-naive MAC-LD who started antibiotic treatment between January 2002 and December 2013, we identified 72 patients with refractory disease, characterized by persistently positive sputum cultures despite ≥12 months of treatment. Molecular analyses of the 23S ribosomal RNA gene responsible for macrolide resistance and serial mycobacterial genotyping were performed using stored MAC isolates. Measurements and Main Results: The median duration of treatment was 32 months (interquartile range, 24-41 mo) in 72 patients. After treatment for a median of 33 months (interquartile range, 21-44 mo), macrolide resistance developed in 16 (22%) patients. Molecular analysis of isolates from 15 patients revealed that 80% (12 of 15) had a point mutation at position 2,058 or 2,059 of the 23S ribosomal RNA gene. Of the 49 patients who had stored preand post-treatment isolates, mycobacterial genotyping revealed that reinfection by new MAC strains occurred in 36 (73%) patients. New MAC strains were found in 24 (49%) patients, and mixed infections with original and new strains occurred in 12 (24%) patients. Only 13 (27%) patients had persistent infections with their original MAC strains. Conclusions: Refractory MAC-LD is commonly caused by reinfection with new strains rather than persistence of the original strain, which may explain the infrequent development of macrolide resistance in refractory MAC-LD.

Original languageEnglish
Pages (from-to)1322-1330
Number of pages9
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume198
Issue number10
DOIs
Publication statusPublished - 2018 Nov 15

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Fingerprint Dive into the research topics of 'Development of macrolide resistance and reinfection in refractory Mycobacterium avium complex lung disease'. Together they form a unique fingerprint.

  • Cite this

    Jhun, B. W., Kim, S. Y., Moon, S. M., Jeon, K., Kwon, O. J., Huh, H. J., Ki, C. S., Lee, N. Y., Shin, S. J., Daley, C. L., & Koh, W. J. (2018). Development of macrolide resistance and reinfection in refractory Mycobacterium avium complex lung disease. American Journal of Respiratory and Critical Care Medicine, 198(10), 1322-1330. https://doi.org/10.1164/rccm.201802-0321OC